Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.30 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17030762 | 0.70 | MAPT (0.40) | HTTPTK2ALDH1A1MAPTSLC2A1 | |
| SCHEMBL22328049 | 0.69 | METAP2 (0.33) | HTTPTK2MAPTSLC2A1IDO1 | |
| SCHEMBL22328038 | 0.69 | NOS1 (0.33) | HTTPTK2MAPTSLC2A1IDO1 | |
| SCHEMBL17030764 | 0.68 | IDO1 (0.43) | ALDH1A1IDO1 | |
| SCHEMBL26880971 | 0.67 | HTT (0.31) | HTTPTK2 | |
| SCHEMBL26553314 | 0.67 | KDM4E (0.39) | HTTPTK2ALDH1A1 | |
| SCHEMBL24854121 | 0.65 | IDO1 (0.40) | IDO1 | |
| SCHEMBL26522473 | 0.65 | NOS1 (0.33) | — | |
| SCHEMBL22328042 | 0.64 | IDO1 (0.36) | ALDH1A1PDPK1IDO1 | |
| SCHEMBL22328051 | 0.64 | PDPK1 (0.41) | ALDH1A1PDPK1CHEK1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230128824-A1 | SPIRO RING-CONTAINING QUINAZOLINE COMPOUND | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128824-A1 | SPIRO RING-CONTAINING QUINAZOLINE COMPOUND | KRAS, NRAS, HRAS | HTT 2868/4885PTK2 2379/4885ALDH1A1 1157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.